Related Experiment Video

Updated: Apr 14, 2026

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.6K

Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines

T-H Hung1, Y-H Li2, C-P Tseng3

  • 1Graduate Institute of Biomedical Sciences, Division of Biotechnology, College of Medicine, Chang Gung University, Tao-Yuan, Republic of China.

Cancer Gene Therapy
|April 25, 2015
PubMed

Insights

Targeting the c-MET pathway with RNA interference effectively induces apoptosis in multidrug-resistant cancer cells. This approach shows promise for overcoming chemotherapy resistance and reducing tumor volume in vivo.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Aberrant c-MET signaling drives cancer progression, including proliferation, survival, and invasion.
  • P-glycoprotein (ABCB1) expression is linked to multidrug resistance (MDR) in cancers, potentially involving the HGF/c-MET pathway.
  • Elevated c-MET and ABCB1 expression correlates with drug resistance in specific cancer cell lines.

Purpose of the Study:

  • To investigate the efficacy of c-MET-targeted RNA interference in inducing apoptosis in ABCB1-overexpressed, multidrug-resistant cancer cells.
  • To evaluate the in vitro and in vivo effects of c-MET downregulation on cancer cell viability and tumor growth.

Main Methods:

  • Utilized c-MET-targeted short hairpin RNA (shRNA) technology for gene silencing.
  • Assessed apoptosis induction and cell viability in vitro in MES-SA/Dx5 and MCF-7/ADR2 cell lines.
  • Evaluated tumor volume reduction in vivo in mice bearing c-MET shRNA-knockdown xenografts.

Main Results:

  • c-MET shRNA transfection led to a dose-dependent decrease in cell viability and a significant increase in apoptosis rates.
  • Downregulation of c-MET expression was confirmed in the treated cell lines.
  • Significant reduction in tumor volume was observed in vivo in mice with c-MET shRNA-knockdown tumors.

Conclusions:

  • Downregulation of c-MET via shRNA effectively induces apoptosis in multidrug-resistant cancer cells.
  • c-MET-targeted RNA interference represents a potential therapeutic strategy to overcome chemotherapy resistance.
  • This approach demonstrates efficacy both in vitro and in vivo, suggesting clinical relevance for treating resistant cancers.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.3K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K